SCHEMBL26685133

SCHEMBL26685133

CC(C)(C)OC(=O)N1CC2(C1)CN(c1cc3nnc(O)cc3cc1C1CC1)C2

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ OXTR P30559 1/20 0.38
▸ AVPR1A P37288 1/20 0.38
▸ KRAS P01116 1/20 0.38
▸ EGLN2 Q96KS0 1/20 0.37
▸ RORC P51449 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ CNR2 P34972 1/20 0.35
▸ SMARCA2 P51531 1/20 0.35
▸ SMARCA4 P51532 1/20 0.35
▸ PBRM1 Q86U86 1/20 0.35
▸ EHMT2 Q96KQ7 1/20 0.35
▸ ACACB O00763 3/20 0.34
▸ GPR119 Q8TDV5 4/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ RET P07949 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ NSD2 O96028 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30632448 1.00 OXTR (0.38) OXTRAVPR1AKRASEGLN2RORC
SCHEMBL30632526 0.86 SMARCA2 (0.50) OXTRAVPR1AKRASEGLN2RORC
SCHEMBL26685126 0.86 SMARCA2 (0.50) OXTRAVPR1AKRASEGLN2RORC
SCHEMBL26685199 0.83 OXTR (0.34) OXTRAVPR1AKRASEGLN2RORC
SCHEMBL30632439 0.83 OXTR (0.34) OXTRAVPR1AKRASEGLN2RORC
SCHEMBL26685440 0.71 EGLN2 (0.42) OXTRAVPR1AKRASEGLN2RORC
SCHEMBL30632460 0.71 EGLN2 (0.42) OXTRAVPR1AKRASEGLN2RORC
SCHEMBL31293862 0.71 OXTR (0.40) OXTRAVPR1AKRASEGLN2CYP11B2
SCHEMBL31570177 0.71 SMYD3 (0.31) —
SCHEMBL31293622 0.68 SMARCA2 (0.53) OXTRAVPR1AKRASEGLN2CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023220129-A1 BENZOYPARAZINE PYRAZINES ANE THEIR USES FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed
Send feedback